Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMES M KRELL

Allopathic & Osteopathic Physicians Dermatology

NPI
1932133659
CMS profile
532194
Location
BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$142,969.98

225 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 225 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMES M KRELL

NPI 1932133659 · CMS profile ID 532194

Allopathic & Osteopathic Physicians / Dermatology

BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 225 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1932133659?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMES M KRELL, NPI 1932133659, CMS profile ID 532194. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 225 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932133659?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JAMES M KRELL, NPI 1932133659, CMS profile ID 532194. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 225 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932133659?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JAMES M KRELL, NPI 1932133659, CMS profile ID 532194, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 225 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1932133659?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

225 matching records · $142,969.98 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 225 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 225.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Dermavant Sciences, Inc. $21.3308/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127893170 CMS
ABBVIE INC. $3.5608/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104109162 CMS
Galderma Laboratories, L.P. $5,400.0008/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145310283 CMS
Galderma Laboratories, L.P. $85.8508/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145310285 CMS
E.R. Squibb & Sons, L.L.C. $35.0307/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101379234 CMS
Galderma Laboratories, L.P. $10.3507/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145310273 CMS
Galderma Laboratories, L.P. $117.6607/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145310275 CMS
Galderma Laboratories, L.P. $35.3407/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145310277 CMS
Galderma Laboratories, L.P. $33.0607/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145310279 CMS
Galderma Laboratories, L.P. $91.2107/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145310281 CMS
Galderma Laboratories, L.P. $474.9607/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145310265 CMS
Galderma Laboratories, L.P. $339.0107/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145310267 CMS
Galderma Laboratories, L.P. $8.1107/26/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145310269 CMS
Galderma Laboratories, L.P. $251.9707/26/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145310271 CMS
ABBVIE INC. $96.1507/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104109160 CMS
E.R. Squibb & Sons, L.L.C. $15.3707/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101379224 CMS
Lilly USA, LLC $1,000.0007/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135018222 CMS
Regeneron Healthcare Solutions, Inc. $38.2907/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114092313 CMS
Regeneron Healthcare Solutions, Inc. $23.0007/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114092315 CMS
Regeneron Healthcare Solutions, Inc. $23.7107/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114092317 CMS
Dermavant Sciences, Inc. $16.3407/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127893166 CMS
Arcutis Biotherapeutics, Inc. $19.0507/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121051325 CMS
ABBVIE INC. $7.6307/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104109158 CMS
LEO Pharma Inc. $21.4507/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152638707 CMS
ABBVIE INC. $2,362.5007/11/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103136455 CMS
ABBVIE INC. $32.7907/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104109156 CMS
Arcutis Biotherapeutics, Inc. $24.8407/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121051323 CMS
ABBVIE INC. $4.0907/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104109154 CMS
UCB, Inc. $1,725.0007/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143285045 CMS
Janssen Biotech, Inc. $127.2407/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078254683 CMS
Lilly USA, LLC $1,000.0007/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135036889 CMS
ABBVIE INC. $4,725.0006/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103159272 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $8.7706/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153810069 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $2,500.0006/14/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118239008 CMS
E.R. Squibb & Sons, L.L.C. $19.7406/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101379216 CMS
E.R. Squibb & Sons, L.L.C. $17.0906/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101379220 CMS
ABBVIE INC. $11.7506/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104109152 CMS
Regeneron Healthcare Solutions, Inc. $4,509.0006/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114092311 CMS
ABBVIE INC. $113.0706/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104109150 CMS
ABBVIE INC. $1,164.1906/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104192406 CMS
UCB, Inc. $5.7605/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143285032 CMS
UCB, Inc. $10.0005/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143285037 CMS
UCB, Inc. $4,000.0005/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143285041 CMS
Amgen Inc. $21.8305/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117301751 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $1,113.3905/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152155935 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $3,971.0005/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152155943 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $124.2605/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152155951 CMS
ABBVIE INC. $8.9205/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104109148 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.9305/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118239006 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $21.8305/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153810087 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $190,369.82 235
PY2020 $103,366.24 102
PY2021 $95,973.59 110
PY2022 $147,005.57 175
PY2023 $136,888.14 173
PY2024 $142,969.98 225
PY2025 $127,347.37 206

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $349,889.97 127
PY2024 Recipient $104.58 1
PY2024 Principal investigator $536,588.94 222
PY2023 Recipient $2,264.00 1
PY2023 Principal investigator $334,687.62 118
PY2022 Recipient $272.00 1
PY2022 Principal investigator $222,449.12 76
PY2021 Principal investigator $389,474.41 86
PY2020 Recipient $1,922.60 2
PY2020 Principal investigator $393,877.45 100
PY2019 Recipient $3,192.59 3
PY2019 Principal investigator $876,709.01 140

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

127 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202534143
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,550.00 12/24/2025 Non-covered Recipient Entity
Total Skin and Beauty Dermatology Center, PC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435278
Principal investigator 1 ABBVIE INC. $1,862.42 12/22/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202531642
Principal investigator 1 ABBVIE INC. $900.00 12/18/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202531152
Principal investigator 1 ABBVIE INC. $282.60 12/18/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202531154
Principal investigator 1 ABBVIE INC. $1,633.50 12/04/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202527070
Principal investigator 1 ABBVIE INC. $6,110.40 12/04/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202527072
Principal investigator 1 Janssen Research & Development, LLC $72.00 12/04/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175161838
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,689.10 12/01/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOL
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289019
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $900.00 11/13/2025 Non-covered Recipient Entity
Total Skin and Beauty Dermatology Center, PC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435263
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,390.00 11/13/2025 Non-covered Recipient Entity
Total Skin and Beauty Dermatology Center, PC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435269
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,227.42 11/13/2025 Non-covered Recipient Entity
Total Skin and Beauty Dermatology Center, PC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435275
Principal investigator 1 ABBVIE INC. $969.00 11/06/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202523331
Principal investigator 1 ABBVIE INC. $4,203.50 11/04/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202520531
Principal investigator 1 Janssen Research & Development, LLC $1,185.40 10/23/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175161787
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,514.50 10/22/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOL
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287257
Principal investigator 1 ABBVIE INC. $100.00 10/16/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202517151
Principal investigator 1 Janssen Research & Development, LLC $144.00 10/16/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175162254
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $900.00 10/16/2025 Non-covered Recipient Entity
Total Skin and Beauty Dermatology Center, PC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435260
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,955.00 10/10/2025 Non-covered Recipient Entity
Total Skin and Beauty Dermatology Center, PC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435256
Principal investigator 1 ABBVIE INC. $1,380.70 10/09/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202514069
Principal investigator 1 ABBVIE INC. $1,086.80 10/09/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202514071
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $618.80 10/08/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOL
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223286497
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $60.00 10/08/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOL
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286565
Principal investigator 1 ABBVIE INC. $828.00 10/07/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202513407
Principal investigator 1 ABBVIE INC. $809.40 10/02/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202513133
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $123.50 09/26/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223285943
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $415.00 09/26/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223285945
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,222.70 09/26/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285983
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $9,000.00 09/11/2025 Non-covered Recipient Entity
Total Skin and Beauty Dermatology Center, PC
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata No dispute reported 06/30/2026 1252797096
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20.00 09/10/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223285261
Principal investigator 1 ABBVIE INC. $1,128.60 09/04/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202509554
Principal investigator 1 ABBVIE INC. $1,424.00 09/03/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202507974
Principal investigator 1 ABBVIE INC. $6,185.90 09/03/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202507976
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,190.20 09/03/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285037
Principal investigator 1 Eli Lilly and Company $27,901.00 08/25/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187891510
Principal investigator 1 ABBVIE INC. $315.36 08/22/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202505611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 08/22/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184229985
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,111.40 08/15/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284355
Principal investigator 1 ABBVIE INC. $1,067.90 08/13/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202504399
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,501.50 08/08/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223283979
Principal investigator 1 ABBVIE INC. $1,470.90 08/05/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202501618
Principal investigator 1 ABBVIE INC. $1,394.30 08/05/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202501620
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,154.90 08/01/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223283615
Principal investigator 1 Janssen Research & Development, LLC $1,185.40 07/31/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175162321
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,385.20 07/23/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223283034
Principal investigator 1 Eli Lilly and Company $3,457.35 07/17/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187891118
Principal investigator 1 Janssen Research & Development, LLC $2,200.00 07/16/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr PC
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175162066
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,955.00 07/16/2025 Non-covered Recipient Entity
Total Skin and Beauty Dermatology Center, PC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435252
Principal investigator 1 ABBVIE INC. $1,086.80 07/08/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202497466
Principal investigator 1 Janssen Research & Development, LLC $400.00 07/03/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr PC
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175161755
Principal investigator 1 Janssen Research & Development, LLC $1,858.00 07/03/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr PC
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175162384
Principal investigator 1 ABBVIE INC. $292.60 07/02/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202496585
Principal investigator 1 ABBVIE INC. $1,352.10 07/02/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202496587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $129.80 06/23/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210054
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $259.00 06/23/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210156
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $259.00 06/23/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210158
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $259.00 06/23/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210160
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.90 06/23/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210318
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.90 06/23/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210320
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.90 06/23/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210322
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.20 06/23/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210428
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $85.80 06/23/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210444
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $85.80 06/23/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210446
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $96.80 06/23/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210458
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $96.80 06/23/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184210460
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,616.00 06/06/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280920
Principal investigator 1 Janssen Research & Development, LLC $1,974.00 06/04/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr PC
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175161735
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 06/04/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr PC
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175161749
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 06/04/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr PC
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175161830
Principal investigator 1 Janssen Research & Development, LLC $218.00 06/04/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr PC
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175161985
Principal investigator 1 Janssen Research & Development, LLC $218.00 06/04/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr PC
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162017
Principal investigator 1 Janssen Research & Development, LLC $218.00 06/04/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr PC
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162050
Principal investigator 1 Janssen Research & Development, LLC $218.00 06/04/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr PC
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162354
Principal investigator 1 ABBVIE INC. $4,097.00 06/03/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202488761
Principal investigator 1 ABBVIE INC. $1,131.40 06/03/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202488763
Principal investigator 1 ABBVIE INC. $1,128.60 06/03/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202488765
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 05/21/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr PC
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175161969
Principal investigator 1 Janssen Research & Development, LLC $201.00 05/21/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr PC
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162122
Principal investigator 1 Janssen Research & Development, LLC $1,092.00 05/21/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr PC
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162216
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,101.65 05/16/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279926
Principal investigator 1 ABBVIE INC. $1,760.00 05/15/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202485165
Principal investigator 1 ABBVIE INC. $1,880.00 05/15/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202485183
Principal investigator 1 Janssen Research & Development, LLC $1,185.40 05/08/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175161825
Principal investigator 1 ABBVIE INC. $4,106.20 05/07/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202483889
Principal investigator 1 ABBVIE INC. $1,086.80 05/07/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202483891
Principal investigator 1 ABBVIE INC. $1,380.70 05/07/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202483893
Principal investigator 1 ABBVIE INC. $15,369.60 05/07/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202483895
Principal investigator 1 Janssen Research & Development, LLC $2,310.00 04/28/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr PC
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175161814
Principal investigator 1 Janssen Research & Development, LLC $504.00 04/23/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175161947
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,746.00 04/18/2025 Non-covered Recipient Entity
Total Skin and Beauty Dermatology Center, PC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435248
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,955.00 04/14/2025 Non-covered Recipient Entity
Total Skin and Beauty Dermatology Center, PC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435244
Principal investigator 1 Eli Lilly and Company $1,500.00 04/11/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED, SINGLE-ARM, PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB No dispute reported 06/30/2026 1187891122
Principal investigator 1 Janssen Research & Development, LLC $332.00 04/07/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr PC
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175162091
Principal investigator 1 ABBVIE INC. $1,635.80 04/03/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202468797
Principal investigator 1 ABBVIE INC. $1,232.40 04/03/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202469028
Principal investigator 1 ABBVIE INC. $1,236.40 04/03/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202469032
Principal investigator 1 Eli Lilly and Company $1,795.17 03/25/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187891120
Principal investigator 1 ABBVIE INC. $9,609.70 03/07/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202459245
Principal investigator 1 ABBVIE INC. $292.60 03/06/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202456464
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,190.20 03/05/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275987
Principal investigator 1 Janssen Research & Development, LLC $6,042.00 03/03/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr PC
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175161887
Principal investigator 1 Janssen Research & Development, LLC $2,310.00 02/27/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr PC
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175161878
Principal investigator 1 Janssen Research & Development, LLC $3,466.00 02/27/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr PC
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162391
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,763.60 02/26/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 02/20/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155088
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 02/20/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155100
Principal investigator 1 Eli Lilly and Company $11,471.60 02/11/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1187891438
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $12,324.38 02/07/2025 Non-covered Recipient Entity
Total Skin and Beauty Dermatology Center, PC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435239
Principal investigator 1 ABBVIE INC. $5,056.00 02/06/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202446754
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 02/05/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184152057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 02/05/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184152059
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,940.90 02/03/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274589
Principal investigator 1 Janssen Research & Development, LLC $201.00 01/29/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr PC
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175161992
Principal investigator 1 Janssen Research & Development, LLC $201.00 01/29/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr PC
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162073
Principal investigator 1 Janssen Research & Development, LLC $1,228.00 01/27/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr PC
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175162397
Principal investigator 1 ABBVIE INC. $100.00 01/22/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202440483
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,342.65 01/22/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274323
Principal investigator 1 Janssen Research & Development, LLC $581.97 01/21/2025 Non-covered Recipient Entity
Total Skin and Beauty Derm Ctr Admn
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175162303
Principal investigator 1 SANOFI US SERVICES INC. $4,355.10 01/21/2025 Non-covered Recipient Entity
Total Skin Beauty Dermatology Center Pc Total Dermatology
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226083336
Principal investigator 1 ABBVIE INC. $400.00 01/20/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202440036
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $12,339.55 01/17/2025 Non-covered Recipient Entity
Total Skin And Beauty Dermatology Center PC
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1235992899
Principal investigator 1 Eli Lilly and Company $26,456.00 01/07/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187893598
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $78.00 01/03/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223273495
Principal investigator 1 ABBVIE INC. $1,686.90 01/02/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202433422
Principal investigator 1 ABBVIE INC. $1,390.40 01/02/2025 Non-covered Recipient Entity
TOTAL SKIN & BEAUTY DERMATOLOGY CEN
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202433426
Principal investigator 1 ABBVIE INC. $218.60 01/02/2025 Non-covered Recipient Entity
TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC
M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202435853